IRIS
MARRAZZO, Agostino
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 10.912
EU - Europa 6.350
AS - Asia 5.477
AF - Africa 886
SA - Sud America 876
OC - Oceania 21
Continente sconosciuto - Info sul continente non disponibili 2
Totale 24.524
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 10.558
SG - Singapore 2.642
RU - Federazione Russa 1.980
IT - Italia 1.902
CN - Cina 1.504
BR - Brasile 729
IE - Irlanda 651
CI - Costa d'Avorio 531
VN - Vietnam 482
UA - Ucraina 398
DE - Germania 310
FR - Francia 304
KR - Corea 272
CA - Canada 264
GB - Regno Unito 179
SN - Senegal 121
NG - Nigeria 112
IN - India 101
FI - Finlandia 99
ES - Italia 89
NL - Olanda 85
JP - Giappone 83
PL - Polonia 79
SE - Svezia 75
BD - Bangladesh 63
HK - Hong Kong 58
AR - Argentina 47
MX - Messico 47
IQ - Iraq 46
ID - Indonesia 42
TR - Turchia 39
ZA - Sudafrica 36
CH - Svizzera 33
UZ - Uzbekistan 29
CZ - Repubblica Ceca 28
AT - Austria 26
EC - Ecuador 25
CL - Cile 19
MA - Marocco 19
BE - Belgio 18
GR - Grecia 18
LU - Lussemburgo 18
VE - Venezuela 18
AU - Australia 17
BJ - Benin 17
KE - Kenya 16
LT - Lituania 15
CO - Colombia 14
IR - Iran 14
LB - Libano 12
SA - Arabia Saudita 12
EG - Egitto 10
JM - Giamaica 10
AE - Emirati Arabi Uniti 9
PK - Pakistan 9
RS - Serbia 9
TN - Tunisia 9
CR - Costa Rica 8
HU - Ungheria 8
IL - Israele 7
MY - Malesia 7
UY - Uruguay 7
AL - Albania 6
BO - Bolivia 6
JO - Giordania 6
NP - Nepal 6
PY - Paraguay 6
DO - Repubblica Dominicana 5
HN - Honduras 5
OM - Oman 5
DZ - Algeria 4
ET - Etiopia 4
KZ - Kazakistan 4
PH - Filippine 4
AO - Angola 3
AZ - Azerbaigian 3
BB - Barbados 3
BG - Bulgaria 3
NZ - Nuova Zelanda 3
PE - Perù 3
PS - Palestinian Territory 3
SY - Repubblica araba siriana 3
TT - Trinidad e Tobago 3
CG - Congo 2
DK - Danimarca 2
GE - Georgia 2
GY - Guiana 2
HR - Croazia 2
LK - Sri Lanka 2
LV - Lettonia 2
PA - Panama 2
RO - Romania 2
SK - Slovacchia (Repubblica Slovacca) 2
TH - Thailandia 2
TW - Taiwan 2
XK - ???statistics.table.value.countryCode.XK??? 2
AG - Antigua e Barbuda 1
BH - Bahrain 1
BS - Bahamas 1
BY - Bielorussia 1
Totale 24.507
Salva come PNG Salva come JPEG
Città #
Dallas 2.133
Singapore 1.621
Santa Clara 1.168
Chandler 916
Moscow 909
San Jose 673
Dublin 647
Ashburn 634
Chicago 561
Abidjan 531
Catania 526
Jacksonville 448
Hefei 346
Boardman 293
Seoul 271
Beijing 241
Civitanova Marche 209
Los Angeles 200
Lauterbourg 193
Nanjing 182
North Charleston 167
Andover 166
Lawrence 166
Cambridge 165
Toronto 143
Ho Chi Minh City 136
Munich 124
Dakar 121
New York 99
Hanoi 93
Council Bluffs 90
Houston 90
Des Moines 84
Rome 77
Wilmington 77
Tokyo 76
Buffalo 75
Bremen 70
São Paulo 68
Naples 67
San Mateo 63
Warsaw 63
Helsinki 59
The Dalles 58
Dong Ket 55
Columbus 54
Lagos 54
Grafing 52
Hong Kong 52
Amsterdam 51
Montreal 49
Saint Petersburg 49
Shenyang 49
Nanchang 48
Orem 44
Abuja 40
Milan 40
Ottawa 38
Atlanta 37
Brooklyn 37
Palermo 37
Denver 36
Hebei 35
Jiaxing 33
Poplar 33
Changsha 32
London 31
Tianjin 30
Johannesburg 28
Florence 27
Da Nang 26
Phoenix 26
Jakarta 25
Rio de Janeiro 24
Stockholm 24
Madrid 23
Messina 23
Belo Horizonte 22
Lappeenranta 21
Leawood 21
Sala Baganza 21
Chennai 20
Haiphong 20
Paris 20
San Francisco 20
Seattle 20
Washington 19
Brno 18
Mexico City 18
Port Harcourt 18
Baghdad 17
Cotonou 17
Misterbianco 17
Brussels 16
Marseille 16
Pune 16
Tashkent 16
Boston 15
Charlotte 15
Falls Church 15
Totale 16.759
Salva come PNG Salva come JPEG
Nome #
How molecular interactions affect crystal morphology: the case of haloperidol 467
Targeting histone deacetylase 1: Inhibition and activation as promising therapeutic strategies for diverse disorders 428
Comprehensive data on a 2D-QSAR model for Heme Oxygenase isoform 1 inhibitors 294
Antioxidant properties and pharmacokinetic studies of new selective σ1 bifunctional ligands 205
(+)-Pentazocine attenuates SH-SY5Y cell death, oxidative stress and microglial migration induced by conditioned medium from activated microglia 204
1-Phenyl-3azabicyclo[3.1.0]hexane derivatives as new ligands for sigma receptors 202
(+)-Pentazocine reduces oxidative stress and apoptosis in microglia following hypoxia/reoxygenation injury 200
Antiproliferative activity of phenylbutyrate ester of haloperidol metabolite II [(±)-MRJF4] in prostate cancer cells 197
Design, synthesis, and pharmacological evaluation of NO donor-sigma receptors hybrids for the treatment of cancer 197
4-Nitro-2,1,3-benzoxadiazole derivatives as potential fluorescent sigma receptor probes 196
Design, synthesis, in vitro evaluation, and molecular modeling studies of N-substituted benzomorphans, analogs of LP2, as novel MOR ligands 194
A novel adamantane derivative attenuates retinal ischemia-reperfusion damage in the rat retina through sigma1 receptors 188
Benzomorphan skeleton, a versatile scaffold for different targets: A comprehensive review 184
(+)-and (−)-Phenazocine enantiomers: evaluation of their dual opioid agonist/σ1 antagonist properties and antinociceptive effects 183
Discovery of SI 1/20 and SI 1/22 as Mutual Prodrugs of 5-Fluorouracil and Imidazole-Based Heme Oxygenase 1 Inhibitor with Improved Cytotoxicity in DU145 Prostate Cancer Cells 180
Development of a Sigma-2 Receptor affinity filter through a Monte Carlo based QSAR analysis 174
HALOPERIDOL METABOLITE II VALPROATE ESTER: ANTIANGIOGENIC ACTIVITY IN HUMAN MICROVASCULAR RETINAL ENDOTHELIAL CELLS 173
A new sigma ligand, (+/-)-PPCC, antagonizes kappa opioid receptor-mediated antinociceptive effect 173
Antiangiogenic Effect of (±)-Haloperidol Metabolite II Valproate Ester [(±)-MRJF22] in Human Microvascular Retinal Endothelial Cells 173
Antioxidant activity of (+)-Pentazocine on activated microglia 172
A new Sigma-1 Receptor antagonist in Chronic Pain Treatment: (+)-2R/S-LP2 effects in inflammatory and neuropathic pain 168
A pseudouridine isoxazolidinyl nucleoside analogue structural analysis: A morphological approach 167
(+)-Methyl (1R,2S)-2-{[4-(4-Chlorophenyl)-4-hydroxypiperidin-1-yl]methyl}-1-phenylcyclopropanecarboxylate [(+)-MR200] Derivatives as Potent and Selective Sigma Receptor Ligands: Stereochemistry and Pharmacological Properties 164
(+)-cis-N-ethyleneamino-N-normetazocine derivatives. Novel and selective sigma ligands with antagonist properties 162
Benzomorphan-based opioid ligands with mixed m agonist/d antagonist activity 159
A structure-and ligand-based virtual screening of a database of “small” marine natural products for the identification of “blue” sigma-2 receptor ligands 159
Benzomorphan scaffold for opioid analgesics and pharmacological tools development: A comprehensive review 155
Haloperidol Metabolite II Valproate Ester (S)-(-)-MRJF22: Preliminary Studies as a Potential Multifunctional Agent Against Uveal Melanoma 155
Adipocyte fatty acid binding protein 4 (FABP4) inhibitors. A comprehensive systematic review 154
Design, Synthesis, and Cytotoxic Assessment of New Haloperidol Analogues as Potential Anticancer Compounds Targeting Sigma Receptors 153
Exploiting the Power of Stereochemistry in Drug Action: 3-[(2S,6S,11S)-8-Hydroxy-6,11-dimethyl-1,4,5,6-tetrahydro-2,6-methano-3-benzazocin-3(2H)-yl]-N-phenylpropanamide as Potent Sigma-1 Receptor Antagonist 152
Antinociceptive profile of LP1, a non-peptide multitarget opioid ligand. 151
Influenza del N-sostituente della (–)-cis-N-Normetazocina nella modulazione del profilo funzionale al MOR, DOR e KOR: da agonista ad antagonista attraverso ligandi misti agonisti/antagonisti 151
Crystal morphologies and polymorphs in tolbutamide microcrystalline powder 150
Sigma-1 and Sigma-2 receptor ligands induce apoptosis and autophagy but have opposite effect on cell proliferation in uveal melanoma 149
Heme Oxygenase Database (HemeOxDB) and QSAR Analysis of Isoform 1 Inhibitors 147
Development of Sigma Receptors Nitric Oxide Photodonor Ligands with Antiproliferative Activity 146
(+)-MR200 derivatives as potential new selective sigma ligands 144
Anti-amnesic properties of (+/-)-PPCC, a novel sigma receptor ligand, on cognitive dysfunction induced by selective cholinergic lesion in rats 143
(+)-Mr200 derivatives: modifications on the amino moiety. In vitro and in vivo pharmacological evaluation 142
Design, synthesis and biological evaluation of novel aminopropylcarboxamide derivatives as sigma ligands 141
Synthesis of “no-light activated” Ciprofloxacin and Norfloxacin derivatives as potential biofilm dispersant agents 140
The Multimodal MOPr/DOPr Agonist LP2 Reduces Allodynia in Chronic Constriction Injured Rats by Rescue of TGF-β1 Signalling 140
Nanoencapsulation strategies for the delivery of novel bifunctional antioxidant/σ1 selective ligands. 139
Novel N-Substituted Benzomorphan-Based Compounds: From MOR-Agonist/DOR-Antagonist to Biased/Unbiased MOR Agonists 139
(+)-MR200 derivatives as potenzial new selective ligands 138
Dual Sigma-1 receptor antagonists and hydrogen sulfide-releasing compounds for pain treatment: Design, synthesis, and pharmacological evaluation 138
Design of Small Molecules for Oncological and Neurodegenerative Diseases 137
Anti-amnesic and neuroprotective actions of the sigma-1 receptor agonist (-)-MR22 in rats with selective cholinergic lesion and amyloid infusion 137
Cytotoxicity Profiles and Neuroprotective Properties of the Novel Ifenprodil Analogues as Sigma Ligands 135
Apoptotic effects of (±) MRJF4 in prostate cancer cells 135
Design and Synthesis of Tetrahydropyrrolo[3,4‐c]Pyrazole Sigma‐1 Receptor Ligands 134
Copper-Catalyzed Coupling Reaction of 2-Thioxo-4-quinazolinone and Thieno[3,2-d]pyrimidin-4-one Methane Sulphonamide with Aryl Iodide : Preparation of Potential COX-2 Selective Inhibitors 133
Nitric Oxide Photo-Donor Hybrids of Ciprofloxacin and Norfloxacin: A Shift in Activity from Antimicrobial to Anticancer Agents 133
Heme Oxygenase-2 (HO-2) as a therapeutic target: Activators and inhibitors 133
Synthesis and Structure-Activity Relationships of LP1 Derivatives: N-Methyl-N-phenylethylamino Analogues as Novel MOR Agonists 131
CNS permeability parameters determination through a statistical analysis driven approach 131
New arylethanolimidazole derivatives as HO-1 inhibitors with cytotoxicity against MCF-7 breast cancer cells 130
The antagonistic effect of the sigma 1 receptor ligand (+)-MR200 on persistent pain induced by inflammation. 129
New selective Sigma-1/HDACi prodrugs for neurodegenerative disorders 129
La modellistica molecolare applicata ai recettori Sigma-1 e Sigma-2: un excursus 129
Discovery of first novel sigma/HDACi dual-ligands with a potent in vitro antiproliferative activity 128
Mu and Delta Opioid Receptor Targeting Reduces Connexin 43-Based Heterocellular Coupling during Neuropathic Pain 128
Design, synthesis, and biological evaluation of new hybrid MOR agonist/HDACi compounds: an innovative approach for persistent pain management 127
In vitro and in vivo studies of ocular topically administered NLC for the treatment of uveal melanoma 126
Tumor Targeting Sigma Receptor Ligands: Development of New Molecular Hybrids as Anticancer Therapeutics 126
Synthesis, in vitro and in vivo characterization of new benzoxazole and benzothiazole-based sigma receptor ligands 126
Development of NO-releasing sigma receptor hybrids as anticancer agents 126
Correction to Nitric Oxide Photo-Donor Hybrids of Ciprofloxacin and Norfloxacin: A Shift in Activity from Antimicrobial to Anticancer Agents 125
Neuroprotective effect of the new sigma receptor ligands cis-(+) and cis-(–)-PPCC 124
Fourfold filtered statistical/computational approach for the identification of imidazole compounds as HO-1 inhibitors from natural products 124
Development of novel H2S-donor sigma receptor hybrids for the management of pain. 124
Sigma-2 receptor ligands QSAR model dataset 123
Novel structural insight into inhibitors of heme oxygenase-1 (ho-1) by new imidazole-based compounds: Biochemical and in vitro anticancer activity evaluation 122
Novel sigma 1-antagonists with cis-(+)-normetazocine scaffold: synthesis, molecular modeling, and antinociceptive effect 121
Novel N-normetazocine Derivatives with Opioid Agonist/Sigma-1 Receptor Antagonist Profile as Potential Analgesics in Inflammatory Pain 121
Novel Sigma-1 receptor antagonists: From opioids to small molecules: What is new? 121
W/O/W Microemulsions for Nasal Delivery of Hydrophilic Compounds: A Preliminary Study 119
Targeting heme Oxygenase-1 with hybrid compounds to overcome Imatinib resistance in chronic myeloid leukemia cell lines 119
Preliminary in vitro and in vivo studies of (S)-(–)-MRJF22 loaded-NLC for potential treatment of uveal melanoma 117
Molecular modeling studies of pseudouridine isoxazolidinyl nucleoside analogues as potential inhibitors of the pseudouridine 5'-monophosphate glycosidase 117
Recent Advances in the Development of Sigma Receptor Ligands as Cytotoxic Agents: A Medicinal Chemistry Perspective 117
Morphing of ibogaine: A successful attempt into the search for sigma-2 receptor ligands 116
New Insights into the Opioid Analgesic Profile of cis-(-)-N-Normetazocine-derived Ligands 115
Discovery of AD258 as a Sigma Receptor Ligand with Potent Antiallodynic Activity 115
Novel Sigma Receptors Ligands-Nitric Oxide Photodonor: Molecular Hybrids for Double-Targeted Antiproliferative Effect 115
Synthesis of potential selective COX-2 enzyme inhibitors derived from ethyl ester of 2-isothiocyanato-5-phenyl-3-thiophenecarboxylic acid 115
Novel Tyrosine Kinase Inhibitors to Target Chronic Myeloid Leukemia 115
Analgesici oppioidi 114
Synthesis and pharmacological evaluation of MRJF4 as new potential anticancer tool 114
Haloperidol Metabolite II Valproate Ester: Antiangiogenic Activity in Human Microvascular Retinal Endothelial Cells 114
Design, Synthesis and biological evaluation of hybrid MOR agonist/ HDACi molecules as potential therapeutic agents for chronic pain treatment 113
Synthesis, in vitro and in silico studies of HO-1 inducers and lung antifibrotic agents 113
Structure-activity relationships of mixed σ1R/σ2R ligands with antiproliferative and anticancer effects 112
Exploring Structural Requirements for Sigma-1 Receptor Linear Ligands: Experimental and Computational Approaches 112
Design, synthesis and biological evaluation of MOR agonist/HDACi hybrid compounds: a new potential therapeutic strategy for persistent pain management 111
Synthesis of (+)-(1'R,2'S) and (1'S,2'R)-6,11 -dimethyl-1,2,3,4,5,6-hexahydro-3-[[2'-(alkoxycarbonyl)-2'- phenylcycloprophy]methyl]-2,6-methano-3-benzazocin-8-ol. Comparison of the affinities for sigma(1) and opioid receptors with in the diastereoisomeric MPCB and CCB 111
The benzomorphan-based LP1 ligand is a suitable MOR/DOR agonist for chronic pain treatment 111
NLC for the delivery of new prodrugs in the treatment of uveal melanoma 110
Synthesis of Novel Benzylpiperazine Derivatives as Ligands for the σ1 Receptor 110
Totale 14.903
Salva come PNG Salva come JPEG
Categoria #
all - tutte 74.283
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 74.283
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021243 0 0 0 0 0 0 0 0 0 0 155 88
2021/20221.302 136 172 28 19 211 20 190 48 103 32 34 309
2022/20232.687 208 157 48 337 219 432 13 469 603 41 116 44
2023/20241.649 80 252 65 97 104 420 84 88 12 40 263 144
2024/20255.330 149 844 242 410 1.006 594 321 229 373 407 343 412
2025/202611.439 721 648 2.396 708 1.621 2.249 1.120 551 668 642 115 0
Totale 25.076